Respiratory syncytial virus: the Beyfortus drug reimbursed

Respiratory syncytial virus: the Beyfortus drug reimbursed
Respiratory syncytial virus: the Beyfortus drug reimbursed

Nirsevimab, known by the brand name Beyfortus®, received approval from the European Medicines Agency (EMA) in 2022. This drug must be administered before the start of the RSV season (October to March) and acts preventively as an antibody. It reduces the number of hospitalizations for babies under 6 months by 80%.

In fact, however, Beyfortus will not be available before September, despite the early start of reimbursement. The pharmaceutical firm (Sanofi, editor’s note) wishes to prevent the drug from being administered too early in this way, justifies the minister’s office.

Reimbursement is provided for 1 box of 50 mg or 100 mg depending on weight (50 mg below 5kg and 100 mg above 5kg) before 1 year. At the pharmacy, parents only pay the co-payment (between 8 and 12.10 euros). The injection must be given by a competent person (such as the general practitioner).

Each year, Sciensano identifies 7,000 cases of RSV infection in our country. Most children have a first infection during their first year of life. In children under two years old, it can develop into pneumonia or bronchiolitis.

An information campaign is planned for this summer, adds the Vandenbroucke firm.

© 2024 Belga Newsbriefing. All rights of reproduction and representation reserved. All information reproduced in this section (dispatches, photos, logos) is protected by intellectual property rights held by Belga Newsbriefing. Therefore, none of this information may be reproduced, modified, redistributed, translated, commercially exploited or reused in any way without the prior written consent of Belga Newsbriefing.

-

-

NEXT Even at 60, go out covered: sexually transmitted diseases are on the rise among “straight people of a certain age”